Patient Selection & Exclusion Criteria
In accordance with the IRB, RCN will carefully monitor patient selection and will be available to resolve questions. RCN will immediately apprise providers when new indications and contraindications arise.
Maintain Registry Clinical Database
Database will track outcomes of primary diseases and comorbidities, patient reported outcomes, provide constant monitoring for optimal safety and efficacy and be maintained as required by the Texas Law.
Data Collection & State Mandated Reporting
Registry data will be posted (annually) as required by Texas law, with no added work required by providers to be compliant
National Marketing & Referral System
Physician Education & Updates
Compliance and Safety
IRB Development and Compliance
As required by Texas law, and as an integral part of providing the best and safest regenerative treatments for patients, Regenerative Care Network will work closely with federally-approved Institutional Review Boards on behalf of our physicians.
Board certified in appropriate specialty for treatment and licensed in the State of Texas
Physician & Staff Training
Training in the following areas: fundamentals of regenerative therapy, Human research (NIH) training/certification, proper technique of cell delivery, product storage and handling, patient pre/post-procedure instructions and informed consent process
MSC Manufacturer Selection
Manufacturer must meet very high standards including: FDA GMP standards with audits, review published and unpublished product data and reputation among peers.
Negotiate Cell Purchase Price
Volume-based purchasing will assure providers the lowest possible price